Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.
You may also be interested in...
Withdrawal of sBLA for full approval of Keytruda in second-line SCCHN makes way for Merck to file for first-line use.
Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.